JANX Janux Therapeutics, Inc.
$17.26▲ +3.42%
Healthcare
Other
Volume 687.2K
Avg Volume (10D) 636.6K
Key Metrics & Fundamentals
Market Cap
$1.06B
P/E Ratio
–
Div Yield
0.00%
52W Range
12.12 - 35.34
% vs 50 MA
-1.73%
% vs 200 MA
13.03%
RSI-14
51.0
MACD Histogram
-0.0300
Beta (1Y vs SPY)
1.08
Free Cash Flow
$12.28M
Gross Rev
$10.27M
Gross Profit
$10.27M
EBITDA
-$31.23M
COGS
–
Operating Exp
$41.96M
Operating Income
-$31.69M
EBIT
-$31.69M
Pretax Income
-$21.97M
Net Income
-$21.97M
EPS (Diluted)
-0.35
Price & Volume History
Loading chart…
Recent News
Ensign Group (ENSG) Beats Q3 Earnings Estimates
Zacks · Oct 27, 2026 5:20 PM ET
Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now?
Simply Wall St. · Oct 13, 2026 5:11 AM ET
Janux Therapeutics (JANX) Stock May Look Overvalued After Its 110% Run
Simply Wall St. · Oct 10, 2026 7:16 AM ET
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Zacks · Sep 30, 2026 6:12 AM ET
Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?
Simply Wall St. · Sep 29, 2026 4:05 PM ET
Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey
Simply Wall St. · Sep 27, 2026 11:07 AM ET
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Zacks · Sep 16, 2026 5:47 AM ET
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Zacks · Sep 15, 2026 10:12 AM ET
Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate
MT Newswires · Sep 14, 2026 9:09 AM ET
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Business Wire · Sep 14, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See JANX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.